Browse by category

Reach Surgical, the surgical solutions division of Genesis MedTech, has received CE Mark approval for iREACH IRIS, a next-generation powered stapling platform designed to deliver Real-Time Firing Curve and up to 90° articulation during surgery. iREACH IRIS Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation Unlike conventional powered staplers that provide general firing feedback, iREACH IRIS Real-Time Firing Curve provides a continuous, location-specific force

More than a quarter of people with Type 2 diabetes take glucagon-like peptide-1 (GLP-1), but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a study by Stanford Medicine scientists and their collaborators. The genetic variants, carried by roughly 10% of the general population, cause a surprising and still mysterious phenomenon that researchers refer to as GLP-1 resistance, in which levels of the hormone GLP-1, which

A systematic review and meta-analysis has indicated that bariatric surgery may reduce the overall risk of breast cancer in women with obesity, according to researchers from China. However, the studies also revealed a paradoxical finding: Despite the overall reduction in risk, the incidence of stage I breast cancer increased in the surgical group. Nevertheless, the study authors acknowledge that as the studies are based on observational data, a causal relationship cannot be co

Study identifies genetic predictors for GLP-1 weight loss efficacy and side effects A large-scale genome-wide association study (GWAS) has identified genetic predictors for GLP-1 weight loss efficacy and side effects. The findings provide direct evidence that variation in the genes targeted by GLP-1 medications contributes to why people respond differently to GLP-1 therapies. Illustration of the biological pathways for the GLP-1 genetic associations identified by the 23andMe

A collaboration between the University of Maryland (UMD) and University of Concepción in Chile has uncovered a communication chain in the brain. The research identified a previously unknown communication chain in the hypothalamus - the region of the brain responsible for regulating hunger and fullness - these findings could eventually point to new ways of targeting appetite-related conditions such as obesity and eating disorders. Brain regulation of appetite. Diagram showing

The FDA has approved Eli Lilly and Company’s Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical problems. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist (GLP-1ra) that can be taken any time of the day without restrictions on food and water intake. "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with n